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Abstract
Intronic GGGGCC repeat expansions in C9orf72 are the most
common known cause of frontotemporal dementia (FTD) and
amyotrophic lateral sclerosis (ALS), which are characterised by
degeneration of cortical and motor neurons, respectively. Repeat
expansions have been proposed to cause disease by both the
repeat RNA forming foci that sequester RNA-binding proteins and
through toxic dipeptide repeat proteins generated by repeat-
associated non-ATG translation. GGGGCC repeat RNA folds into a
G-quadruplex secondary structure, and we investigated whether
targeting this structure is a potential therapeutic strategy. We
performed a screen that identified three structurally related small
molecules that specifically stabilise GGGGCC repeat G-quadruplex
RNA. We investigated their effect in C9orf72 patient iPSC-derived
motor and cortical neurons and show that they significantly
reduce RNA foci burden and the levels of dipeptide repeat proteins.
Furthermore, they also reduce dipeptide repeat proteins and
improve survival in vivo, in GGGGCC repeat-expressing Drosophila.
Therefore, small molecules that target GGGGCC repeat G-quadru-
plexes can ameliorate the two key pathologies associated with
C9orf72 FTD/ALS. These data provide proof of principle that target-
ing GGGGCC repeat G-quadruplexes has therapeutic potential.
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Introduction
Expansions of a GGGGCC repeat within the first intron of the
C9orf72 gene are the most common genetic cause of both amyo-
trophic lateral sclerosis (ALS) and frontotemporal dementia (FTD),
two rapidly progressive and incurable neurodegenerative disorders
(Dejesus-Hernandez et al, 2011; Renton et al, 2011). While the
general population carries < 30 GGGGCC (G4C2) repeats, with
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approximately 90% of individuals carrying < 8 repeats, large
hexanucleotide repeat expansions (HRE), typically between 800 to
> 4,000, are causative of ALS and FTD (Beck et al, 2013; van Blitter-
swijk et al, 2013). HREs are transcribed and the resulting RNA
forms nuclear foci and can also be translated in all reading frames
into dipeptide repeat proteins (DPRs) through a non-canonical
process termed repeat-associated non-ATG (RAN) translation (Ash
et al, 2013; Gendron et al, 2013; Lagier-Tourenne et al, 2013;
Mizielinska et al, 2013; Mori et al, 2013a,b; Zu et al, 2013). Both
repeat RNA and DPRs have been proposed to drive pathogenesis:
foci can sequester RNA-binding proteins (RBPs) and therefore
impair their function (Haeusler et al, 2016), while DPRs have been
proven to be toxic in numerous disease models (Mizielinska et al,
2014; Wen et al, 2014; Zhang et al, 2016).
G4C2 RNA can fold to form the highly stable non-canonical G-
quadruplex (G-Q) conformation (Fratta et al, 2012), a four-stranded
structure formed by the stacking of planar tetrads of four non-
sequential guanosine residues (G-quartets). RNA G-Qs are able to
form in vivo (Biffi et al, 2014), are enriched in RNA 50 and 30 UTRs
(Huppert et al, 2008) and are known to be involved in regulating
numerous RNA functions, including splicing, RNA transport and
translation (Simone et al, 2015). As G-Qs can directly affect transla-
tion (Bugaut & Balasubramanian, 2012), and G4C2 G-Qs have been
shown to specifically sequester disease-relevant RBPs (Haeusler
et al, 2014; Conlon et al, 2016), they may play an important role in
both RNA foci and DPR toxicity.
Small molecules binding to both DNA and RNA G-Qs have been
identified (Di Antonio et al, 2012), and due to the different confor-
mation of RNA and DNA G-Q molecules, ligands preferentially
targeting RNA G-Qs have also been developed (Biffi et al, 2014).
Identification of molecules that specifically target C9orf72 repeat
RNA could have therapeutic potential by shielding pathogenic inter-
actions of the C9orf72 expanded RNA with RBPs, and/or by interfer-
ing with RAN translation. We report here a screen identifying
molecules with selectivity for the G4C2 G-Q RNA and show they are
able to reduce both RNA foci formation and RAN translation in
C9orf72 iPSC-neuron models and C9orf72 repeat-expressing flies.
Results
Identification of small molecules that preferentially stabilise RNA
G4C2 G-quadruplexes
In order to identify small molecules that preferentially stabilise RNA
G4C2 G-Qs, we adapted a FRET-based G-Q melting assay (Guyen
et al, 2004; Collie et al, 2012), to specifically report G4C2 G-Q stabili-
sation. We have previously identified several novel G-Q-binding
chemotypes in the chemical library from the anti-parasitic drug
discovery programme at Georgia State University based on non-
conjugated aromatic diamidines (Ohnmacht et al, 2014). Here, we
screened 138 small molecules, 104 from this library and 34 previ-
ously established G-Q-binding compounds (Schultes et al, 2004;
Moore et al, 2006). We measured their ability to stabilise (G4C2)4
oligonucleotides composed of either RNA or DNA folded into G-Qs.
44/138 small molecules increased the melting temperature (Tm) of
(G4C2)4 RNA by greater than 13°C. Twelve of these showed at least
5°C greater stabilisation of (G4C2)4 RNA than (G4C2)4 DNA (Fig 1A).
Strikingly, three of these molecules (DB1246, DB1247, DB1273,
green circles in Fig 1A) had very similar chemical structures, dif-
fering by only two atoms (Fig 1B), indicating a genuine structure–
function relationship. No other compounds in the compound set
have similar features of two linked five-membered rings.
We therefore took these three small molecules forward for further
testing. A stabilisation dose response for both sense (G4C2)4 (Fig 1C)
and antisense (Appendix Fig S1) (G2C4)4 RNA and DNA oligonu-
cleotides confirmed the preferential stabilisation of RNA G4C2 G-Qs
by DB1246, DB1247 and DB1273. Circular dichroism (CD) spec-
troscopy confirmed that the (G4C2)4 RNA formed the expected paral-
lel G-Q structure, with a minimum at 236 nm and a maximum at
264 nm. Each of the three small molecules caused the appearance of
a characteristic additional induced CD signal in a separate region of
the spectrum (350–550 nm; Fig 1D), while the small molecules alone
gave no CD signal (Appendix Fig S2), thus confirming direct binding
of DB1246, DB1247 and DB1273 to (G4C2)4 RNA G-Qs. We derived
the Tm from our CD denaturation curves, which confirmed that
(G4C2)4 RNA G-Qs were stabilised in the presence of each small mole-
cule (Appendix Fig S3). These compounds bind to the RNA G4C2
repeat G-Q with high affinities, with Kd values in the range ca 200–
400 nM (measurements by fluorescence anisotropy, Appendix Fig
S4). These data identify, using FRET, CD and fluorescence anisotropy
techniques, three structurally related small molecules DB1246,
DB1247 and DB1273 that bind and stabilise RNA G4C2 G-Qs.
RNA G4C2 G-quadruplex-binding small molecules reduce RNA foci
in patient iPSC-neurons
We next determined whether the small molecules could alleviate the
key pathologies associated with C9orf72 G4C2 repeat expansion in
patient-derived iPSC-neurons. We first characterised three patient
iPSC lines (described in Appendix Table S1). We confirmed the pres-
ence of G4C2 repeat expansions by Southern blotting, which were
maintained following differentiation into either motor or cortical
neurons (Appendix Fig S5). Cortical neurons were prepared using an
established differentiation protocol (Shi et al, 2012; Sposito et al,
2015). Spinal motor neurons were generated using dual-SMAD and
GSK3b inhibition followed by caudal and ventral patterning to the
pMN domain and finally promoting cell cycle exit using a Notch
antagonist (Hall et al, 2017), yielding 90% pure motor neuron
cultures (Fig EV1). The efficiency of differentiation did not differ
between C9orf72 and control lines (Fig EV1). We also confirmed that
RNA foci were specifically observed in patient iPSC-motor and iPSC-
cortical neurons (Appendix Fig S6). We next performed a dose
response in one patient iPSC-cortical neuron line to investigate the
effect of DB1246, DB1247 and DB1273 on RNA foci formation. For
each of the small molecules, a 1 lM treatment for 4 days reduced
RNA foci burden (Fig EV2). We therefore treated cortical neurons
derived from all three independent C9orf72 repeat expansion iPSC
lines with 1 lM of DB1246, DB1247 or DB1273 for 4 days. Each small
molecule significantly reduced RNA foci burden by approximately
50% (Fig 2). The same treatment on iPSC-motor neurons derived
from the three independent patient lines showed that DB1246 and
DB1273 reduced RNA foci burden, again by approximately 50%,
while DB1247 did not significantly reduce RNA foci burden. These
data show that small molecules that bind RNA G4C2 G-Qs can reduce
RNA foci in both iPSC-motor and iPSC-cortical neurons.
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Figure 1. Identification and structure of small molecules that preferentially stabilise RNA G4C2 repeat G-quadruplexes.
A A FRET assay was used to measure the difference in melting temperature (DTm) of (G4C2)4 RNA or DNA G-Qs in the presence of 2 lM of 138 different small molecules.
An increase in DTm indicates stabilisation of the G-Q. Small molecules are ranked on the x-axis according to their increasing thermal stabilisation of the DNA (G4C2)4
G-Q. Small molecules that preferentially stabilise RNA over DNA (G4C2)4 G-Qs reside in the upper part of the scatter plot, above the blue curve. An arbitrary DTm
threshold of 13°C greater than vehicle (grey line) and a differential binding to RNA over DNA (DTmRNA–DTmDNA ≥ 5°C) were used to select candidate small
molecules.
B Structures of the three compounds (DB1246, DB1247, DB1273), highlighted by green circles in (A), that show preferential binding to RNA (G4C2)4 G-Qs and were
further characterised.
C FRET dose response of DB1246, DB1247 and DB1273 on stabilisation of RNA or DNA (G4C2)4 G-Qs.
D Temperature unfold CD spectra for (G4C2)4 RNA alone (which shows a characteristic G-Q structure with minima at 237 nm, maxima at 264 nm and no additional
signal), or in the presence of 2 lM DB1246, DB1247 or DB1273. A characteristic induced CD spectrum, in the 350–550 nm region, is observed only in the presence of
each small molecule, confirming that each of these three compounds are binding to (G4C2)4 RNA G-Qs.
Data information: Data in (A) represent mean  SD, n = 1 with three technical replicates. Data in (C) represent mean  SD, n = 3 independent experiments. Data in (D)
represent mean  SD, n = 3 independent experiments.
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RNA G4C2 G-quadruplex-binding small molecules reduce
dipeptide repeat proteins in patient iPSC-neurons without
causing toxicity
We next addressed whether DB1246, DB1247 or DB1273 could
reduce the other major pathology in C9FTD/ALS—dipeptide repeat
proteins. We established an MSD ELISA for poly(GP) and showed
that poly(GP) is specifically detected in C9orf72 repeat expansion
iPSC-motor and iPSC-cortical neurons (Appendix Fig S7). Treatment
with 1 or 4 lM of DB1246, DB1247 or DB1273 for 4 days did not
reduce poly(GP) levels in iPSC-motor neurons (Appendix Fig S8),
indicating a differential response of RNA foci and poly(GP) to the
small molecules. We therefore investigated 7-day treatments with a
range of concentrations (8, 12 and 16 lM). We focused on iPSC-
motor neurons due to their shorter differentiation protocol
compared to cortical neurons. We found that the two small mole-
cules that reduced RNA foci in iPSC-motor neurons, DB1246 and
DB1273, also significantly reduced poly(GP) levels (Fig 3A).
DB1273 was the most effective, significantly reducing poly(GP) at
all concentrations, with greater than 50% reduction at 16 lM.
Importantly, expression levels of C9orf72 transcripts were not
affected by the same treatment (Fig 3B), indicating a direct effect on
G4C2 repeat G-Q RNA, rather than a more general effect on tran-
scription. We also measured the expression levels of MCM2 as it has
a G-Q within its core promoter region (Huppert & Balasubramanian,
2007), and its expression is reduced by the G-Q-binding small mole-
cule TMPyP4 (Liu et al, 2014). The levels of MCM2 were unaffected
(Fig 3B), indicating specificity of the small molecules for G4C2 RNA
G-Qs. We assessed the toxicity of DB1246, DB1247 and DB1273 in
iPSC-motor neurons using a concentration range from 0.05 to
40 lM. Importantly, no toxicity was observed in the dose range that
reduces poly(GP) levels (Fig 3C). A similar toxicity profile was also
observed in human fibroblasts (Appendix Fig S9). These data show
that small molecules that bind RNA G4C2 G-Qs can specifically
reduce the levels of dipeptide repeat proteins generated by endoge-
nous RAN translation of G4C2 repeats in cultured patient neurons,
without causing toxicity.
RNA G4C2 G-quadruplex-binding small molecules reduce
dipeptide repeat proteins and improve survival in GGGGCC
repeat-expressing Drosophila
We treated Drosophila with adult-onset ubiquitous expression of 36
G4C2 repeats (Mizielinska et al, 2014) for 7 days with the most effec-
tive small molecule, DB1273, by feeding it to adult flies in liquid
food. While food intake was no different across treatment groups
(Appendix Fig S10), DB1273 led to a significant and dose-dependent
decrease in poly(GP) levels (Fig EV3A and B). Liquid food did not
support the flies long enough to determine whether DB1273 was also
able to ameliorate the decreased survival of adult (G4C2)36 flies. We
therefore delivered DB1273 to larvae in solid food, since effects on
survival can be observed more rapidly in larvae and larvae eat more
than adult flies, allowing delivery of an increased amount of
compound. Constitutive, ubiquitous expression of (G4C2)36 in
A
B
Figure 2. G4C2 repeat G-quadruplex binding small molecules reduce RNA foci in patient iPSC-cortical and iPSC-motor neurons.
A Representative images of C9orf72 iPSC-cortical neurons treated with DMSO (vehicle control) or 1 lM of DB1246, DB1247 or DB1273, for 4 days. RNA foci are shown in
red and nuclei (DAPI) in blue. Scale bar represents 10 lm.
B Quantification shows RNA foci are significantly reduced by all three compounds in iPSC-cortical neurons and by DB1246 and DB1273 in iPSC-motor neurons. Data are
shown as the average percentage of neurons containing RNA foci relative to vehicle (DMSO). N = 3 independent C9orf72 patient lines with two to three inductions
per line and at least 70 neurons counted per induction, data are shown as mean and SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-sample two-tailed t-test versus
normalised control. For cortical neurons, *P = 0.0124 (DB1246), **P = 0.0065 (DB1247), **P = 0.0096 (DB1273). For motor neurons, ***P = 0.0004 (DB1246),
**P = 0.0030 (DB1273).
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Drosophila larvae is toxic, with 24% of larvae dying before the pupal
stage (Fig 3D). Treatment of first-instar larvae with DB1273 for
7 days led to a significant increase in survival to the pupal stage
(Fig 3D). We have shown that poly(GR) is the DPR responsible for
toxicity in our G4C2 repeat expansion flies (Mizielinska et al, 2014).
We therefore developed a poly(GR) MSD immunoassay (Fig EV4).
Poly(GR) was specifically detected in (G4C2)36 larvae and treatment
with DB1273 significantly decreased poly(GR) levels by 33%
(Fig 3E). The level of expression of the G4C2 transgene in treated
larvae was not affected (Appendix Fig S11) indicating a specific
effect on RAN translation rather than an effect on the transgene
itself. In addition, the same treatment in control larvae did not cause
toxicity (Appendix Fig S12). We used the inherent fluorescence of
DB1273 to examine the biodistribution of DB1273 in our treated
larvae. DB1273 was broadly distributed throughout the gut, includ-
ing the epithelium, while in other tissues, including the central
nervous system, infrequent fluorescent puncta were consistently
observed in all three replicates (Fig EV5). Overall, these data show
A D
EB C
Figure 3. G4C2 repeat G-quadruplex binding small molecules reduce poly(GP) in patient iPSC-motor neurons and reduce dipeptide repeat proteins and
improve survival in GGGGCC repeat-expressing Drosophila.
A Poly(GP) levels were measured by MSD immunoassay in C9orf72 patient iPSC-motor neurons treated for 7 days with 8–16 lM of the G4C2 repeat G-Q-binding small
molecules DB1246, DB1247 and DB1273. Treatment with DB1246 or DB1273 leads to a significant reduction in poly(GP) levels relative to vehicle-treated controls. Data
are shown as the mean and SEM of three independent C9orf72 iPSC lines, with one to six differentiations per line. **P = 0.0068 (DB1246, 12 lm), *P = 0.0417
(DB1246, 16 lm), *P = 0.0196 (DB1247, 8 lm), ***P = 0.0002 (DB1273, 8 lm), *P = 0.0194 (DB1273, 12 lm), **P = 0.0062 (DB1273, 16 lm), one-sample two-tailed
t-test versus normalised control.
B C9orf72 patient iPSC-motor neurons were treated for 7 days with 16 lM of each small molecule and the expression levels of MCM2 and the three C9orf72 transcript
variants (V1–V3) measured by quantitative RT–PCR. Data are shown as the mean and SD of three independent iPSC-motor neuron lines (one induction per line)
relative to vehicle (DMSO)-treated controls. No significant changes in gene expression were observed, one-way ANOVA, Dunnett’s post hoc test, P > 0.05.
C XTT cell death assay for C9orf72 iPSC-motor neurons treated for 7 days with 0–40 lM of DB1246, DB1247, DB1273 or cisplatin as a positive control. Data are shown
as the mean and SEM of two independent iPSC-motor neuron lines. Toxicity is only observed at the highest dose of 40 lM and not at the penultimate dose of
20 lM.
D Drosophila first-instar larvae expressing 36 G4C2 repeats were placed on food containing either vehicle or 1 mM DB1273, and the number reaching the pupal stage of
development counted after 7 days. DB1273 treatment (n = 1,200 flies) significantly improves survival compared to vehicle (n = 1,150 flies), *P = 0.0320, chi-squared
test. Data are shown as proportion reaching the pupal stage, with numbers within each group indicated on the bars. Genotype was w1118; UAS-36(GGGGCC)/+;
daGAL4/+ (daGAL4>36R).
E Drosophila first-instar larvae ubiquitously expressing 36 G4C2 repeats (36R) were treated with vehicle or 1 mM DB1273 for 5 days, until the third-instar stage (L3), and
poly(GR) measured by MSD immunoassay. Poly(GR) was also measured in control (w1118) larvae that do not express G4C2 repeats. DB1273 treatment significantly
reduced poly(GR) expression, data are shown as mean  SEM. n = 8 for 36R groups, n = 7 for control group. ***P = 0.0001 (w1118 versus 36R 0 mM larvae),
**P = 0.0019 (0 mM versus 1 mM 36R larvae), one-way ANOVA with Dunnett’s post hoc test. Genotypes were w1118; and w1118; UAS-36(GGGGCC)/+; daGAL4/+
(daGAL4>36R).
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that small molecules that bind RNA G4C2 G-Qs can reduce dipeptide
repeats levels in vivo and importantly this leads to functional benefit.
Discussion
We identify and characterise three small molecules that share struc-
tural similarity and the ability to bind and stabilise G4C2 RNA G-Qs.
We demonstrate that these molecules can reduce the frequency of
nuclear RNA foci, and the levels of DPRs in C9orf72 patient iPSC-
derived neurons. Furthermore, we provide evidence of in vivo effi-
cacy by showing that they can reduce DPRs and improve the
survival of GGGGCC repeat-expressing Drosophila. Importantly, we
observed a significant reduction in poly(GR), the DPR responsible
for toxicity in our fly model (Mizielinska et al, 2014) as well as
other models (Moens et al, 2017), and thus likely more clinically
relevant than poly(GP). We note that despite limited biodistribution,
the small molecule DB1273 was still able to exert a small but signifi-
cant beneficial in vivo effect on survival. This provides proof of prin-
ciple for targeting G-Q RNA in C9FTD/ALS and indicates that
optimising CNS penetrance will lead to even greater efficacy.
DNA and RNA C9orf72 HREs have been shown to form both G-
Qs and hairpin structures (Fratta et al, 2012; Reddy et al, 2013;
Haeusler et al, 2014; Su et al, 2014; Sket et al, 2015). It is widely
accepted that HREs exert a toxic gain of function, either linked to
RNA-mediated sequestration of RBPs in RNA foci, or through trans-
lation into toxic DPRs (Mizielinska & Isaacs, 2014). Previous work
has shown that targeting the hairpin conformation of HREs, through
small molecules, is a successful approach to reduce both RNA foci
and DPRs (Su et al, 2014). Here, we demonstrate significant reduc-
tions of both RNA foci and DPRs are also possible by targeting the
HRE G-Q conformation.
The effect of our small molecules on G4C2 RNA in patient
neurons is consistent with the presence of RNA G-Q structures
in vivo, as shown using G-Q-specific antibodies (Biffi et al, 2014),
including specifically in C9orf72 patient lines (Conlon et al, 2016).
Interestingly, it has been reported that most predicted RNA G-Qs are
unfolded in eukaryotic cells (Guo & Bartel, 2016). As the C9orf72
HRE represents a very favourable sequence for G-Q formation, our
small molecules may enhance and stabilise folding of G4C2 RNA into
G-Qs in vivo, as has been reported for other RNA G-Q-binding
ligands (Biffi et al, 2014). Small molecule-mediated stabilisation of
G4C2 RNA G-Qs could decrease RNA foci either through facilitating
their degradation or masking the HRE RNA from the FISH probe,
with either scenario indicating effective target engagement. The
decrease we observe in DPRs is consistent with reports that G-Qs in
the 50 UTRs of several genes inhibit translation, with inhibition
enhanced by the addition of G-Q-binding small molecules (Bugaut &
Balasubramanian, 2012; Biffi et al, 2014). While our compounds
were able to reduce both RNA foci and poly(GP) DPRs, the effect on
foci was more rapid and obtained at lower small-molecule concen-
trations. This may be due to the high stability of poly(GP), which
requires 10 days of anti-C9orf72 antisense oligonucleotide treatment
to be significantly reduced in C9orf72 iPSC-neurons (Gendron et al,
2017).
RNA and DNA G-Qs have numerous differences in terms of both
conformation, binding partners and regulation, and small molecules
have been developed to differentiate between them (Di Antonio
et al, 2012). We successfully adopted a DNA/RNA parallel screening
approach to identify small molecules preferentially targeting HRE
RNA. In support of preferential binding to RNA G-Qs, we observed
no impact on transcription levels of MCM2, a transcript with a DNA
G-Q in its core promoter, which was previously shown to be
reduced by TMPyP4 (Liu et al, 2014), a generic G-Q-binding mole-
cule that can also bind G4C2 RNA in vitro (Zamiri et al, 2014). In
summary, these results provide proof of principle for the further
development of drugs that selectively bind G4C2 RNA G-Qs as a ther-
apeutic strategy for C9FTD/ALS.
Materials and Methods
FRET G-quadruplex melting assay
The FRET assay was performed as previously described (Guyen
et al, 2004; Collie et al, 2012). Briefly, DNA and RNA dual-labelled
oligonucleotides (50-FAM and 30-TAMRA) of sequence (G4C2)4 and
(G2C4)4 (IDT, Leuven, Belgium) were initially dissolved as a
100 lM stock in water and diluted to 1 lM in 10 mM sodium
cacodylate buffer (pH 7.35) and annealed by heating to 98°C for
10 min, followed by cooling to room temperature in the heating
block. Small molecules were stored as 10 mM stock solutions in
DMSO; final solutions (2× concentrations) were prepared by dilu-
tion in sodium cacodylate buffer (pH 7.35). 96-well plates (Bio-
Rad) were prepared by aliquoting 50 ll of the annealed oligonu-
cleotide into each well, followed by 50 ll of the compound solu-
tions, which were tested at both 1 and 2 lM. Fluorescence
measurements were made on a DNA Engine Opticon (MJ
Research) with excitation at 450–495 nm and detection at 515–
545 nm. Fluorescence readings were taken at intervals of 0.5°C
over the range 30–100°C, with a constant temperature being main-
tained for 30 s prior to each reading to ensure a stable value. Final
analysis of the data was carried out using a custom script written
in Origin 7.0 (OriginLab Corp., Northampton, MA).
Circular dichroism spectroscopy
Circular dichroism experiments were performed at temperatures
between 15°C and 95°C, with a 1°C/min temperature gradient, using
a Jasco J715 spectropolarimeter (Jasco Hachioji, Tokyo, Japan)
equipped with a Jasco peltier temperature control system. The CD
spectrum from 180 to 600 nm was measured for 1 lM pre-folded
(G2C4)4 RNA, either alone or in the presence of each small molecule
(2 lM) in 10 mM sodium cacodylate (pH 7.35). The Tm was calcu-
lated by fitting the curve to the Van’t Hoff equation using Grafit 5
(Erithacus Software). A CD spectrum of the buffer was recorded and
subtracted from all raw signals before plotting using GraphPad
Prism 5.
iPSC-cortical and iPSC-motor neuron cultures
Primary fibroblast lines were generated from skin biopsies, which
were obtained under informed consent. Ethical permission for this
study was obtained from the National Hospital for Neurology and
Neurosurgery and the Institute of Neurology joint research ethics
committee. Fibroblasts were reprogrammed as previously described
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(Sposito et al, 2015). iPSCs were cultured in feeder-free conditions
on Geltrex-coated plates in Essential 8 medium (Thermo Scientific).
iPSCs were passaged with 0.5 mM EDTA (Thermo Scientific). Corti-
cal neuron differentiation was as previously described (Shi et al,
2012; Sposito et al, 2015). Briefly, iPSCs were plated at 100% con-
fluency and the media switched to neural induction media (1:1
mixture of N-2 and B-27-containing media supplemented with the
SMAD inhibitors Dorsomorphin and SB431452 (Tocris)). Medium
consists of DMEM/F-12 GlutaMAX, 1× N-2, insulin, L-glutamine,
non-essential amino acids, b-mercaptoethanol, penicillin, strepto-
mycin, Neurobasal, 1× B-27 (Thermo Scientific). Media were
changed daily during neural induction, and at the end of the induc-
tion period (day 10–12), the converted neuroepithelium was
replated onto laminin-coated plates using dispase (Thermo Scien-
tific) and maintained in neural maintenance media (a 1:1 mix of N-2
and B-27) which was replaced every 2–3 days. At around days 25–
35, neuronal precursors were passaged further with accutase
(Thermo Scientific) and plated for the final time at day 35 onto
poly-ornithine and laminin-coated plates (Sigma), before being used
in experiments between days 55 and 65. Motor neuron differentia-
tion was as recently described (Hall et al, 2017). Briefly, iPSCs were
plated at 100% confluency and the media switched to motor neuron
induction media (1:1 mixture of N-2 and B-27-containing media
supplemented with the SMAD inhibitors Dorsomorphin and
SB431452 (Tocris) and GSK-3b inhibitor CHIR99021). After a 6-day
induction period, the converted neuroepithelium was replated onto
laminin-coated plates using dispase (Thermo Scientific) and
maintained in a 1:1 mix of the described N-2 and B-27 media
supplemented with 0.5 lM retinoic acid (Sigma) and 1 lM Purmor-
phamine (Calbiochem) for a further 7 days, then maintained in a
1:1 mix of the described N-2 and B-27 media supplemented with
0.1 lM Purmorphamine (Calbiochem) for 4 days. Motor neuron
precursors were replated onto laminin-coated plates using EDTA
(Thermo Scientific) and maintained in a 1:1 mix of the described
N-2 and B-27 media supplemented with 0.1 lM compound E (Milli-
pore) before being used at day 30.
RNA in situ hybridisation
iPSC-derived neurons were fixed in 4% methanol-free formaldehyde
(Pierce) for 10 min at room temperature, dehydrated in a graded
series of alcohols, air-dried and rehydrated in phosphate-buffered
saline (PBS), permeabilised for 10 min in 0.1% Triton X-100 in PBS,
briefly washed in PBS and incubated for 30 min in pre-hybridisation
solution (40% formamide, 2× SSC, 1 mg/ml tRNA, 1 mg/ml salmon
sperm DNA, 0.2% BSA, 10% dextran sulphate, 2 mM ribonucle-
oside vanadyl complex) at 67°C. Hybridisation solution (40%
formamide, 2× SSC, 1 mg/ml tRNA, 1 mg/ml salmon sperm DNA,
0.2% BSA, 10 % dextran sulphate, 2 mM ribonucleoside vanadyl
complex, 0.2 ng/ll (C4G2)4 LNA probe, 50 TYE563-labelled, Exiqon)
was incubated with the cells for 2 h at 67°C. Cells were washed for
30 min at 67°C with high-stringency buffer (2× SSC, 0.1% Triton X-
100) and then for 20 min each, in 0.2× SSC buffer. Nuclei were
stained by DAPI. Coverslips were then dehydrated in 70% and
100% EtOH and mounted onto slides in Vectashield for iPSC-cortical
neurons or Dako mounting medium for iPSC-motor neurons. Images
were acquired using an LSM710 confocal microscope (Zeiss) using a
plan-apochromat 40×/1.4 NA oil immersion objective.
Nuclear RNA foci quantification
Five to ten z-stacks were acquired for each field and at least four
independent fields were imaged. For iPSC-cortical neurons, maxi-
mum intensity projections of each z-stack were analysed in Fiji-
ImageJ and nuclear RNA foci automatically counted by using the
analyse particles function to identify nuclei and the find maxima
function to identify RNA foci in each nucleus. For iPSC-motor
neurons, blinded manual counting of maximum intensity projec-
tions was performed. At least 70 neurons were counted for each
independent differentiation.
MSD immunoassays
A poly(GP) Meso Scale Discovery (MSD) immunoassay was estab-
lished using our previously generated rabbit anti-poly(GP) anti-
body (Mizielinska et al, 2014). A poly(GR) MSD immunoassay
was established using newly generated affinity purified rabbit
anti-(GR)7 antibodies (Eurogentec). The assays were performed as
previously described (Su et al, 2014). Briefly, iPSC-neurons were
lysed in RIPA buffer with protease inhibitors (Roche complete
mini EDTA-free) and then sonicated using a Soniprep 150 (Renais-
sance Scientific Limited) probe sonicator. Lysates were centrifuged
at 16,000 g to remove insoluble material. Drosophila L3 larvae
were frozen in liquid nitrogen, and two larvae per replicate were
homogenised in ice-cold RIPA buffer (Sigma) with protease inhibi-
tors (Roche complete mini EDTA-free). Lysis was allowed to
proceed on ice for 10 minutes, before lysates were centrifuged at
21,000 g for 20 min at 4°C and supernatant was collected in fresh
tubes. The protein concentration of the lysates was determined
using the DC protein assay (Bio-Rad) following manufacturer’s
instructions and equal amounts of protein used in the immunoas-
say. Capture was performed with either unlabelled anti-poly(GP)
or anti-poly(GR) antibodies. Detection on an MSD sector imager
utilised either sulfo-tagged anti-poly(GP) antibody or biotinylated
anti-poly(GR) antibody followed by sulfo-tagged streptavidin. For
iPSC-neurons, prior to analysis, the average reading from a cali-
brator containing no peptide was subtracted from each reading.
For Drosophila larvae, an individual wild-type (w1118) value was
chosen at random and subtracted from all samples to correct for
background, and resultant negative values were considered to be
0. A four-parameter logistic regression curve was fit to the values
obtained using the peptide calibrators using GraphPad Prism, and
concentrations interpolated. Specificity was confirmed with a
peptide cross-reactivity assay using (GP)7, (PR)7 or (GR)7
synthetic peptides (Biogenes) at a concentration of 100 ng/ml.
The lower limit of detection was calculated after fitting a four-
parameter logistic regression curve using the MSD workbench 4.0
software.
XTT assay
iPSC-motor neurons in 96-well plates were treated for 7 days with
0, 0.1, 0.2, 0.3, 0.6, 1.3, 2.5, 5, 10, 20 and 40 lM of DB1246,
DB1247, DB1273 or cisplatin as a positive control. Cell viability was
measured using the XTT assay kit II (Roche) according to the manu-
facturer’s instructions and absorbance measured with a Tecan Spark
10M plate reader.
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Quantitative RT–PCR
iPSC-derived motor neurons were treated with each of the three
small molecules (DB1246, DB1247, DB1273) at 16 lM final
concentration for 7 days and compared to the DMSO vehicle. Total
RNA was extracted in duplicate for each condition using TRIzol
(Invitrogen) and treated with DNase I (Roche). cDNA was synthe-
sised using 1 lg of total RNA for all samples, with a SuperScript
III first-strand cDNA synthesis kit (Invitrogen) and an equimolar
mixture of oligo dT and random hexamer primers. Real-time qRT–
PCR was carried out using Power SYBR Green Master Mix
(Applied Biosystems) for MCM2. TATA-binding protein (TBP) and
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used
as housekeeping genes to normalise across different samples.
Additionally, expression of three alternative C9orf72 transcript
variants (V1, V2, V3) was measured using two custom-designed
fluorescent LNA PrimeTime probes (IDT) and previously
described isoform-specific primers (Fratta et al, 2013). The ampli-
fied transcripts were quantified using the comparative Ct method
and presented as normalised fold expression (DDCt). Oligonu-
cleotide sequences are provided in Appendix Table S2.
Drosophila stocks and husbandry
All fly stocks were maintained at 25°C on a 12-h:12-h light:dark
cycle at 60% constant humidity and on standard sugar–yeast–agar
(SYA) medium (agar, 15 g/l; sugar, 50 g/l; autolyzed yeast, 100 g/l;
nipagin, 100 g/l; and propionic acid, 2 ml/l). A fly line expressing
36 GGGGCC repeats (36R), under the upstream activating sequence
(UAS) promoter, was used (Mizielinska et al, 2014). Expression in
adults was driven using the inducible daughterless-GeneSwitch
(da-GS) driver which was kindly provided by Veronique Monnier
(Tricoire et al, 2009). Expression in larvae was driven with the
constitutive daughterless-GAL4 (daGAL4) driver (Bloomington
Drosophila Stock Center).
Adult Drosophila small-molecule treatments
Two days after eclosion, adult daGS>36R flies were fed with
liquid food administered via capillaries containing 100 lM RU486
to induce expression of the repeats, or with no RU486 as a
control, for 7 days. In addition, flies induced with RU486 were
treated with vehicle or DB1273 at 200 lM or 500 lM concentra-
tions. Flies were housed at a density of five flies per vial in plastic
vials filled with 2 ml of 1% agar, to ensure humid conditions.
Vials were sealed with Parafilm perforated with four holes using a
26-G needle to ensure adequate air circulation. Two graduated 10-
ll disposable glass capillary tubes were held in place through the
Parafilm using truncated 200-ll pipette tips. The liquid food
consisted of 5% (wt/vol) sucrose, 2% yeast extract and blue food
dye to aid visualisation of the liquid in the capillaries. A mineral
oil overlay was used at the top of the capillary to minimise evapo-
ration. An identical chamber without flies was included to deter-
mine evaporative losses. Capillaries were replaced with fresh
liquid food as required, and the volume of food ingestion was
measured over the course of 7 days. After 7 days, flies were snap-
frozen in liquid nitrogen for analysis of abdominal poly(GP) levels
by immunoblotting.
Larval small-molecule treatments
To investigate DB1273 toxicity in vivo, control daughterless-GAL4
(daGAL4)/+ first-instar larvae were placed into vials containing
90% SYA food, supplemented with vehicle (water and DMSO at a
final concentration of 0.3%) or DB1273 to a 0.5 or 1 mM concentra-
tion, at a density of 50 larvae per vial, and the number reaching the
pupal and adult stage of development were counted. To investigate
DB1273 efficacy, daGAL4>36R first-instar larvae were placed into
vials containing 90% SYA food, supplemented with either vehicle or
DB1273 to a 1 mM concentration, at a density of 50 larvae per vial.
The number reaching the pupal stage of development was counted
7 days later by an observer blinded to the experimental conditions.
Third-instar larvae treated with vehicle or DB1273 to a 1 mM
concentration were frozen for RNA and protein analysis.
Immunoblotting
Fly abdomens were homogenised in 20 ll per abdomen of 2×
Laemmli sample buffer (4% SDS, 20% glycerol, 120 mM Tris–HCl
pH 6.8, 200 mM DTT with bromophenol blue) and heated to 95 °C
for 10 min. Samples were centrifuged at 21,000 g for 2 min, and
supernatants were separated on Nu-PAGE 4-12% Bis–Tris gels in
MES running buffer, and then transferred onto nitrocellulose
membranes in a Tris–Glycine transfer buffer with 20% methanol.
Membranes were incubated with rabbit anti-poly(GP) (Mizielinska
et al, 2014) 1:1,000 or mouse anti-a-tubulin, Sigma T6199, 1:2,000
The paper explained
Problem
Amyotrophic lateral sclerosis and frontotemporal dementia are devas-
tating degenerative diseases with no treatments currently available. A
mutation in the C9orf72 gene is the most common cause of both
amyotrophic lateral sclerosis and frontotemporal dementia, account-
ing for approximately 10% of all cases. The C9orf72 mutation is
termed a repeat expansion as it consists of six DNA bases, GGGGCC,
that are repeated thousands of times. The GGGGCC repeat DNA is
transcribed into repeat RNA, which we have previously shown folds
into a distinct secondary structure termed a G-quadruplex. The repeat
RNA is then translated into repetitive proteins, termed dipeptide
repeat proteins, which are extremely neurotoxic. Therefore, reducing
the levels of these dipeptide repeat proteins is a potential therapeutic
strategy.
Results
We performed a screen to identify compounds that specifically target
the C9orf72 RNA G-quadruplex. We identified three compounds with
similar chemical structures that were able to selectively bind the
C9orf72 repeat G-quadruplex RNA. We then treated C9orf72 patient-
induced pluripotent stem cell (iPSC)-derived neurons, and fruit flies
harbouring the C9orf72 repeat expansion, with these compounds. We
found that the compounds reduced the levels of the damaging dipeptide
repeat proteins in both the iPSC-neurons and the fruit flies. Furthermore,
they improved the survival of the C9orf72 repeat fruit flies.
Impact
These results provide proof of principle that targeting the C9orf72
GGGGCC repeat RNA G-quadruplex is a potential treatment strategy
for amyotrophic lateral sclerosis and frontotemporal dementia caused
by C9orf72 repeat expansion.
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followed by horseradish peroxidase-tagged secondary antibody (anti-
rabbit HRP, ab6721 or anti-mouse HRP, ab6789, Abcam, 1:10,000).
Specific binding was detected with Luminata Forte (Millipore) and
imaged with an ImageQuant LAS4000 (GE Healthcare Life Sciences).
Intensity of bands was quantified using Fiji-ImageJ Software.
Statistics
For iPSC-neuron small-molecule effects on RNA foci and poly(GP)
levels, we normalised to the control value for each replicate (inde-
pendent induction) and performed a one-sample t-test of treatment
replicates versus the control value of 1. For comparison of motor
neuron differentiation efficiency between C9orf72 and control iPSCs,
a Mann–Whitney U-test was performed due to unequal variances.
For Drosophila small-molecule treatments, poly(GP) levels were
normalised to the loading control, a-tubulin, and a one-way ANOVA
performed with Dunnett’s post hoc test across the treatment groups.
For comparing lethality/viability in Drosophila, a chi-square test
was used. For quantitative PCR, a t-test was used for comparison of
two groups and a one-way ANOVA with Dunnett’s post hoc test for
comparison of more than two groups. Statistical analyses were
performed in GraphPad Prism 5.
Expanded View for this article is available online.
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